Nexgel, Inc.: what the price is pricing in
The price implies an owner-earnings margin of 0.9%; the company has kept -45.6%. That gap is wide enough for a short position this quarter. Switch lens below to see the same question asked of earnings, growth, sales and book value.
No published rating for Nexgel, Inc.: only 1 valuation models apply; a rating needs 3. The readings below run our models backwards for research and show how trading the gap would have done; they are not a valuation or a rating. The valuation page shows the models and their status.
What profit margin is the price paying for?
The price implies an owner-earnings margin of 0.9%; the company has kept -45.6%.
Market more optimistic than our model: short this quarter
Over time
$10,000 trading the gap vs the S&P 500
Skill or luck?
In plain English: Across 10 quarters with a position, this lens beat the S&P 500 in 8, by +20.5% a quarter on average. That is suggestive but could still be chance. One company is a small sample: the results across all companies are the better guide.
| Positions | Quarters | Beat the S&P 500 | Average vs S&P 500, a quarter | Typical (median), a quarter | A year | Confidence (t) | Evidence |
|---|---|---|---|---|---|---|---|
| Longs | 0 | — | — | — | — | — | — |
| Shorts | 10 | 80.0% | +20.5% | +27.1% | +51.8% | 1.66 | Some evidence |
| All positions | 10 | 80.0% | +20.5% | +27.1% | +51.8% | 1.66 | Some evidence |
Every quarter (11)
| From | Price paid | Margin the price implies | Margin delivered | Position | NXGL | S&P 500 |
|---|---|---|---|---|---|---|
| September 30, 2026 (open) | $0.17 | 0.9% | -45.6% | Short | +9.5% | −0.8% |
| June 30, 2026 | $0.50 | 1.1% | -42.9% | Short | −65.5% | +2.4% |
| March 31, 2026 | $0.63 | 1.7% | -46.5% | Short | −20.9% | +15.1% |
| December 31, 2025 | $1.61 | 3.6% | -54.8% | Short | −60.7% | −4.4% |
| September 30, 2025 | $2.44 | 5.3% | -60.0% | Short | −34.0% | +2.7% |
| June 30, 2025 | $2.58 | 6.2% | -66.7% | Short | −5.4% | +8.1% |
| March 31, 2025 | $2.98 | 7.8% | -78.3% | Short | −13.4% | +10.8% |
| December 31, 2024 | $4.46 | 14.2% | -95.1% | Short | −33.2% | −4.3% |
| September 30, 2024 | $2.58 | 10.5% | -111.5% | Short | +72.9% | +2.5% |
| June 30, 2024 | $2.16 | 8.0% | -119.3% | Short | +19.4% | +5.8% |
| March 31, 2024 | $2.73 | 11.3% | -133.3% | Short | −20.9% | +4.4% |
What return on equity is the price paying for?
No current reading. The latest is from June 30, 2026: the figures this lens needs have not been filed recently enough (or no longer apply), so there is no position this quarter.
Over time
$10,000 trading the gap vs the S&P 500
Skill or luck?
In plain English: Across 10 quarters with a position, this lens beat the S&P 500 in 8, by +20.5% a quarter on average. That is suggestive but could still be chance. One company is a small sample: the results across all companies are the better guide.
| Positions | Quarters | Beat the S&P 500 | Average vs S&P 500, a quarter | Typical (median), a quarter | A year | Confidence (t) | Evidence |
|---|---|---|---|---|---|---|---|
| Longs | 0 | — | — | — | — | — | — |
| Shorts | 10 | 80.0% | +20.5% | +27.1% | +51.8% | 1.66 | Some evidence |
| All positions | 10 | 80.0% | +20.5% | +27.1% | +51.8% | 1.66 | Some evidence |
Every quarter (10)
| From | Price paid | Return on equity the price implies | Return on equity delivered | Position | NXGL | S&P 500 |
|---|---|---|---|---|---|---|
| June 30, 2026 | $0.50 | 8.7% | -69.9% | Short | −65.5% | +2.4% |
| March 31, 2026 | $0.63 | 9.4% | -58.7% | Short | −20.9% | +15.1% |
| December 31, 2025 | $1.61 | 17.4% | -58.3% | Short | −60.7% | −4.4% |
| September 30, 2025 | $2.44 | 26.5% | -66.1% | Short | −34.0% | +2.7% |
| June 30, 2025 | $2.58 | 25.2% | -62.8% | Short | −5.4% | +8.1% |
| March 31, 2025 | $2.98 | 25.0% | -62.8% | Short | −13.4% | +10.8% |
| December 31, 2024 | $4.46 | 40.0% | -68.0% | Short | −33.2% | −4.3% |
| September 30, 2024 | $2.58 | 25.7% | -65.4% | Short | +72.9% | +2.5% |
| June 30, 2024 | $2.16 | 18.7% | -54.9% | Short | +19.4% | +5.8% |
| March 31, 2024 | $2.73 | 22.5% | -51.2% | Short | −20.9% | +4.4% |
How the test works
At each quarter end since March 2010 we rebuild the models from Nexgel, Inc.'s quarters ending at least 90 days earlier (and no more than 200 days before that), using the figures as later filed, including any restatement, and value them at that day's close, adjusted for later share splits and spin-offs so that price and share count are on the same basis. A wide enough gap is a long or a short for one quarter (growth 10 points; margin and return on equity 5 points; a PEG under 0.75 or over 3), measured on total return against the S&P 500. The rules were set before the test. No trading or borrowing costs; today's list of companies. Not investment advice. All companies and the results across them.
Compare with peers
- Sintx Technologies, Inc. priced in
- Orasure Technologies Inc priced in
- Mimedx Group, Inc. priced in
- Organogenesis Holdings Inc. priced in
- UFP Technologies Inc priced in
Head to head: NXGL vs SINTNXGL vs OSURMDXG vs NXGL
More: Health Care Supplies stocks compared, Health Care sector, rankings of US companies